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The life cycles of apicomplexan parasites progress in accord-
ance with fluxes in cytosolic Ca2. Such fluxes are necessary for
events like motility and egress from host cells. We used geneti-
cally encodedCa2 indicators (GCaMPs) to develop a cell-based
phenotypic screen for compounds thatmodulate Ca2 signaling
in the model apicomplexan Toxoplasma gondii. In doing so, we
took advantage of the phosphodiesterase inhibitor zaprinast,
which we show acts in part through cGMP-dependent protein
kinase (protein kinase G; PKG) to raise levels of cytosolic Ca2.
We define the pool of Ca2 regulated by PKG to be a neutral
store distinct from the endoplasmic reticulum. Screening a
library of 823 ATP mimetics, we identify both inhibitors and
enhancers of Ca2 signaling. Two such compounds constitute
novel PKG inhibitors and prevent zaprinast from increasing
cytosolic Ca2. The enhancers identified are capable of releas-
ing intracellularCa2 stores independently of zaprinast or PKG.
One of these enhancers blocks parasite egress and invasion and
shows strong antiparasitic activity against T. gondii. The same
compound inhibits invasion of the most lethal malaria parasite,
Plasmodium falciparum. InhibitionofCa2-relatedphenotypes
in these two apicomplexan parasites suggests that depletion of
intracellular Ca2 stores by the enhancer may be an effective
antiparasitic strategy. These results establish a powerful new
strategy for identifying compounds that modulate the essential
parasite signalingpathways regulatedbyCa2, underscoring the
importance of these pathways and the therapeutic potential of
their inhibition.
Apicomplexan parasites, such as Toxoplasma gondii and
Plasmodium spp., the causative agents of toxoplasmosis and
malaria, require changes in cytosolic Ca2 concentrations to
egress from host cells and move within the infected organism
(1–6). These pathways therefore hold tremendous therapeutic
potential, not only due to their importance in parasite biology
but because of their divergence from similar pathways in host
cells. Compounds targeting Ca2 signaling in parasites have
been shown to be effective antiparasitics (discussed below).
However, few of the molecules involved in regulating Ca2
homeostasis and signaling have been identified in parasites, and
their interplay is only evident in live cells. This has created a
need for new methods to study Ca2 signaling pathways in
apicomplexan parasites, with the hope of defining the essential
components and identifying novel inhibitors.
The mechanisms for Ca2 entry into the cytoplasm and the
physiologically relevant sources of Ca2 remain poorly defined
in apicomplexan parasites. Ca2 can be mobilized from the
parasite’s intracellular stores, or it can be drawn from the envi-
ronment. Current evidence points toward intracellular stores
being sufficient for parasites to move between cells (6–8),
although virulence of T. gondii is enhanced by extracellular
Ca2 (9). The best studied of these intracellular stores is the
endoplasmic reticulum (ER).2 This organelle is a highly net-
worked, dynamic structure (10) that has been shown to consti-
tute multiple spatially independent Ca2 stores in some cell
types (11). Such compartmentalization has also been hypothe-
sized to occur in T. gondii (4). Mammalian cells store Ca2 in
endosomes, lysosomes (12), and the Golgi (13), in addition to
the ER (14). Some alveolates, like Paramecium, additionally
contain a network of alveolar sacs that sequester Ca2 in an
ATP-dependent manner, with physiologically relevant affini-
ties (15, 16). Whether the inner membrane complex, an api-
complexan structure homologous to alveolar sacs, also stores
Ca2 remains to be determined. Like many other eukaryotes,
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apicomplexans also possess acidic vacuoles known as acidocal-
cisomes that contain Ca2 in complex with pyrophosphate and
polyphosphates. This Ca2 can be released pharmacologically,
but the function of acidocalcisomes remains unclear in apicom-
plexans (17). A final acidic Ca2 store described in T. gondii is
the plantlike vacuole or vacuolar compartment. The plantlike
vacuole is an acidic organelle that releases Ca2 upon treat-
ment with L-phenylalanine-naphthylamide (GPN), which in
other systems causes ion leakage from lysosomal compart-
ments (18). Although implicated in ionic homeostasis, these
phenotypes have not been linked to the plantlike vacuole’s
function as a Ca2 store (18). Due to the lack of characterized
regulatable Ca2 channels, it remains an open question which
of these Ca2 sources are involved in parasite motility and
invasion.
Recent evidence suggests that PKG may play a role in regu-
lating parasite Ca2. In Plasmodium berghei, PKG has been
proposed to influence Ca2 homeostasis, thereby regulating
egress from host cells. Activation of PKG leads to change in the
levels of the lipid precursors of inositol 1,4,5-triphosphate (IP3).
This has been hypothesized to increase IP3, which causes
release of Ca2 from the ER through binding to the IP3 recep-
tor, although such a channel remains to be identified in apicom-
plexan parasites (19). PKG is also known to regulate egress in
T. gondii, although its effect on parasite Ca2 has not been
determined (20). In both parasites, PKG can be pharmacologi-
cally activated using the mammalian phosphodiesterase inhib-
itor zaprinast (20, 21). In Plasmodium, zaprinast treatment
leads to an increase in cyclic GMP levels that presumably acti-
vates PKG (22). Further characterization of zaprinast’s mecha-
nism of action could therefore shed light on Ca2 signaling.
Targeting the downstream effectors of Ca2 signaling has
been shown to hold therapeutic value against T. gondii. Com-
pounds targeting Ca2-dependent protein kinase 1, a regulator
of egress and invasion, reduce proliferation in cell culture and
cyst burden in the brains of T. gondii-infected mice (23, 24).
Drugs targeting Ca2-related processes are appealing not only
because of this historical success but also because many pro-
teins involved in parasite Ca2 signaling are sufficiently diver-
gent from their mammalian counterparts to enable the design
of drugs with minimal off-target effects. For example, protein
kinase G (PKG), which regulates egress, invasion, and motility
in T. gondii and Plasmodium spp. (19, 20, 25, 26), is sufficiently
different frommammalian PKG to be selectively inhibited (27).
Similarly, the Ca2-dependent protein kinases lack homo-
logues in mammalian cells (28), making them attractive drug
targets.
In this study, we use both chemical and genetic Ca2 indica-
tors to define the regulatory circuits that mediate Ca2 release
in T. gondii and identify small molecules that modulate this
process. We determine the effect of T. gondii PKG on cytosolic
Ca2 following treatment with zaprinast and characterize the
source of the Ca2 released in this process as a neutral store
distinct from the ER. Using genetically encoded Ca2 indica-
tors recently established in T. gondii (29), we develop a cell-
based phenotypic screen that allows us tomonitor Ca2 signal-
ing in live cells without the technical challenges of conventional
chemical Ca2 indicators. Using this platform, we have been
able to identify, in an unbiased manner, compounds that inter-
fere with Ca2 signaling. In contrast to enzyme-based assays,
this system enables us to probe a broader swath of parasite
biology. Recent analysis indicates that such phenotypic screens
are more likely to lead to clinically approved drugs than the far
more prevalent molecular target-based approaches (30). Our
screen identified two novel PKG inhibitors that abrogate the
effect of zaprinast, aswell as two compounds that increase cyto-
solic Ca2 through an independent pathway. From the latter,
one compound blocks invasion of both T. gondii and Plasmo-
dium falciparum. Our results demonstrate the potential of this
strategy to explore parasite Ca2 signaling and identify new
compounds with antiparasitic potential against multiple api-
complexan parasites.
Experimental Procedures
Strain Construction and Maintenance—Recombinant hu-
man T. gondii strain RH parasites were maintained in human
foreskin fibroblasts (HFFs) grown in DMEM supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and 10
g/ml gentamicin. PKG-T and PKG-M alleles were con-
structed as described previously (31). GCaMP5 was amplified
from pCMV-GCaMP5G (32) with primers containing NsiI and
PacI restriction sites (forward primer, 5-gcg atg cat cct ttt tcg
aca aaa tgg gtt ctc atc atc atc atc atc; reverse primer, 5-gcg tta
att aat cac ttc gct gtc atc att tg) and cloned directionally, replac-
ing the CAT gene in pSAG1/2-CAT (33) to generate pSAG1-
GCaMP5. Recombinant human parasites were co-transfected
with pSAG1-GCaMP5 and pSAG1/2-CAT and selected with
chloramphenicol (40 M), and clones were isolated by limiting
dilution. The GCaMP6f strains was similarly derived, as
described previously (29). Both GCaMP strains were main-
tained under selection to prevent loss of the transgene. The
GFP-expressing strain was kindly provided by Jeroen P. J. Saeij
(34).
Store Activation and Cpd1 Inhibition Experiments with
GCaMP6f—GCaMP6f-expressing T. gondii were suspended at
2 107 parasites/ml in basal Ca2 buffer (140mMNaCl, 10mM
potassium gluconate, 2.7 mM MgSO4, 2 mM glucose, 250 M
EGTA, 85 M CaCl2, 10 mM HEPES, pH 7.3) or extracellular
Ca2 buffer (140mMNaCl, 10mMpotassiumgluconate, 2.7mM
MgSO4, 2 mM glucose, 1 mM CaCl2, 10 mM HEPES, pH 7.3),
supplemented with 1% FBS when noted. For the Cpd1 inhibi-
tion experiments, parasiteswere suspended inRinger’s solution
(115 mM NaCl, 3 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 3 mM
NaH2PO4, 10 mMHEPES, 10 mM glucose, 1% FBS). In all cases,
100l of suspended parasites were applied to eachwell of a Cell
Carrier 96-well plate (PerkinElmer Life Sciences). For store
activation experiments, parasites were incubated on ice for 5
min before the addition of Enh1 or Enh2 (10 M final concen-
tration), zaprinast (100 M final), or DMSO (0.3% final) sus-
pended in the same buffers as the parasites to which they were
added. To examine the effect of Cpd1 on zaprinast or Enh1
treatment of GCaMP6-expressing parasites, fluorescence was
recorded for 100 s before adding Cpd1 to a concentration of 1.2
M. Fluorescence was recorded for an additional 300 s before
treatment with 10MEnh1 or 100M zaprinast. Parasites were
incubated on ice for 5 min before the addition of zaprinast to
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slow down the response and facilitate observation of peak fluo-
rescence. Fluorescence was read with an excitation wavelength
of 485 nm and an emission wavelength of 528 nm every 10 s in
a BioTek Cytation 3. The assay plate was shaken for 1 s before
each read.
Compound Screen—GCaMP5-expressing parasites were sus-
pended in Ringer’s solution at 4 107 parasites/ml, and 50l of
parasites were applied to each well of a 96-well plate (Costar,
catalog no. 3631). Parasites were treated with compounds from
theGSK libraries PKIS andPKIS2 at 13.3Mor 1.33%DMSOas
a vehicle control and then incubated at 37 °C with 5% CO2 for
10 min. Parasites were then treated with 100 M zaprinast or
0.1%DMSO as a vehicle control and incubated at 37 °Cwith 5%
CO2 for an additional 4 min before measuring fluorescence
with excitation and emission wavelengths of 485 and 525 nm,
respectively, on a SpectraMax M3 (Molecular Devices). Basal
fluorescence, measured from untreated parasites, was sub-
tracted from all values, and results were expressed as -fold
change from parasites treated only with zaprinast. Z factors
were determined from (i) parasites treatedwith zaprinast versus
untreated parasites and (ii) parasites treated with a final con-
centration of 1 M Cpd2 or a vehicle control followed by zapri-
nast, using the formula,Z  1 3(pn)/(pn), where
p and n indicate S.D. values of positive and negative controls,
and p and n indicate the means of positive and negative con-
trols, respectively.
In Vitro PKG Assays—Recombinant T. gondii PKG was
expressed using a baculovirus system. Synthetic DNA coding
for the protein was amplified and subcloned into the pFBOH-
MHL vector, which confers an N-terminal His6 tag with a
tobacco etch virus cleavage site. The resulting plasmid was
transformed into DH10BacTM Escherichia coli competent cells
to produce recombinant viral DNA. P3 viral stockswere used to
infect Sf9 insect cells grown in HyQ SFX insect serum-free
medium (Thermo Fisher Scientific). The culture was incubated
at 27 °C and shaken at 100 rpm. After 60–72 h, the cells were
harvested. TheHis-taggedT. gondiiPKG sampleswere purified
by affinity chromatography and size exclusion chromatography
using an ÄKTAxpress system equipped with a SuperdexTM 200
10/300 column (GE Healthcare, Mississauga, Canada). In vitro
kinase assays were performed using a PKG assay kit (CycLex) as
per the manufacturer’s instructions. Inhibitors were tested
against 6.76 nM recombinant PKG, which was active within the
linear range of the assay.
Structural Analysis—Structures of various protein kinases in
complexwith pyrazolopyridazine (PP) and oxindole derivatives
were obtained from the RCSB Protein Data Bank (35) and
aligned on the basis of their kinase domains. For the PP analysis,
the CDK2 structures 3EID and 3EJ1 (36) and the p38 MAPK
structure 3GCP (37) were aligned to the ERK2 structure 1WZY
(38). For the oxindole analysis, the PDK1 structures 2PE0 and
2PE2 (39) and the Alk5 structure 2X7O were aligned to the
Nek2 structure 2JAV (40).
Lactate Dehydrogenase Release Egress Assays—Confluent
HFF monolayers in 96-well plates were infected with 5  104
parasites/well. The HFFmonolayer was washed once with Rin-
ger’s solution 18 h later, and 50 l of Ringer’s solution was
applied to eachwell. Drugs suspended in Ringer’s solutionwere
applied at 1.33 times the indicated concentrations. 1.33%
DMSO in Ringer’s solution was used as a vehicle control. Cells
were incubated at 37 °C with 5% CO2 for 20 min, stimulated
with 500 M zaprinast or 0.5% DMSO (vehicle), and incubated
again for an additional 5 min. The cells were centrifuged at
400 g for 5 min, before collecting 50 l of each supernatant.
The lactate dehydrogenase levels in the supernatant samples
were quantified using the CytoTox 96 cytotoxicity assay (Pro-
mega) as per the manufacturer’s instructions.
PlaqueAssays—T. gondiiparasiteswere suspended in growth
mediumsupplementedwith Enh1, zaprinast, orDMSOalone at
the indicated concentrations. The amount of DMSO in all
treatment groups was normalized to 0.1%. Parasites were incu-
bated at 37 °C with 5% CO2 for 20 min before infecting HFF
monolayers in 6-well plates using 3 ml carrying 100 parasites/
well. Medium containing the highest concentration of each
drug was also applied to HFF cells in the absence of parasites to
assess the effects of the drugs onhost cell viability. The parasites
were allowed to plaque for 8 days before fixingwith 70% ethanol
and staining with 0.1% crystal violet.
Lytic Assays—Drugs were suspended at twice the indicated
concentrations in growth medium and mixed with an equal
volume of parasites at an initial concentration of 106 parasites/
ml. The maximum concentration of DMSO was added as a
vehicle control: 1% DMSO in comparisons with zaprinast and
0.013% in comparisons with Enh1. Parasites were preincubated
with the compounds for 20min at 37 °C with 5%CO2, and then
200l/well (105 parasites) was added to host cell monolayers in
96-well plates. Assay plates were incubated at 37 °C with 5%
CO2 for 3 days and then fixed in 70% ethanol and stained with
0.1% crystal violet. Absorbance at 590 nmwas read as ameasure
of host cell lysis.
Cell-wounding Assays—Parasites suspended in Ringer’s solu-
tion at 5 105 parasites/ml were pretreated with varying con-
centrations of zaprinast (as indicated) for 20 min at 37 °C with
5% CO2. 105 parasites/well were then applied to confluent host
cell monolayers, and plates were centrifuged at 290  g for 5
min. Following 1 h at 37 °C with 5% CO2, plates were centri-
fuged again at 500  g for 5 min. 50 l of supernatant were
collected from each well, and lactate dehydrogenase was quan-
tified using the CytoTox 96 cytotoxicity assay (Promega).
Video Microscopy Egress Assays—Host cell monolayers in
Cell Carrier 96-well plates (PerkinElmer Life Sciences) were
infected with 5  104 GFP-expressing parasites/well. 18 h
postinfection, themediumwas exchanged for Ringer’s solution,
and the intracellular parasites were treated with 10 M Enh1,
500 M zaprinast, or 0.5% DMSO. Images were acquired every
10 s for 30min. Tomeasure the effect of Enh1 on zaprinast and
A23187-induced egress, the procedure was repeated, adding
either 12.5 M Enh1 or 0.13% DMSO and imaging for 10 min,
before stimulation with 500M zaprinast or 1MA23187 (Cal-
biochem) and imaging for an additional 10 min. In all cases,
imageswere acquiredwith a4 objective on aCytation3 reader
(BioTek) using excitation and emission wavelengths of 485 and
528 nm, respectively. Intact vacuoles were defined as objects of
at least 78m2with a circularity of at least 0.5, as determined in
Fiji after default thresholding (41).
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Video Microscopy—Parasites expressing GCaMP5 were
transfected with p30-DsRed and used to infect host cell mono-
layers in 3-cm glass bottom dishes (MatTek). Approximately
20 h after infection, medium was exchanged for Ringer’s solu-
tion, and parasites were imaged on a Nikon Eclipse Ti epifluo-
rescence microscope, equipped with an enclosure heated to
37 °C. Images were acquired every 5 s for 10 min following the
addition of zaprinast to a final concentration of 100 M. To
quantify changes in fluorescence, videoswere analyzed in Fiji to
measure the average fluorescence intensity in specific circular
regions of interest 10m in diameter. To examine the effects of
zaprinast and Enh1 on mammalian cells, 6  103 HeLa cells
were seeded in eachwell of aCell Carrier 96-well plate. Approx-
imately 24 h later, HeLa cells were transfected with 100 ng of
the pCMV-R-GECO (42) using Fugene (Promega) as per the
manufacturer’s instructions. Cells were washed in Ringer’s
solution and then treated with 10 M Enh1, 500 M zaprinast,
or 2MA23187. Images were acquired every 12 s for 30min on
a Cytation3 reader (BioTek) using an excitation wavelength of
531 and an emission wavelength of 593. Higher resolution vid-
eos were similarly acquired from HeLa cells seeded in 3-cm
glass bottom dishes (MatTek) and transfected with 200 ng of
pCMV-R-GECO per dish. Cells were treatedwith either 500M
zaprinast or 10 M Enh1 in Ringer’s solution and imaged every
250 ms using a Nikon Eclipse Ti microscope. Videos were ana-
lyzed in Fiji using default thresholding for the red channel to
determine the mean gray value in each slice for individual cells.
Kymographs were constructed from videos of intracellular
GCaMP6f-expressing parasites, following the same treatment
as for the video microscopy egress assays, except half as many
parasites were used to infect the monolayers, and a20 objec-
tive was used to acquire the images. Regions of interest were
defined by outlining parasites in Fiji and measuring the mean
fluorescence of each region over time.
Fura-2 Recordings—Tachyzoite loadingwith Fura-2/AMwas
done as described previously (17). Briefly, freshly lysed parasites
werewashed twicewith bufferA (116mMNaCl, 5.4mMKCl, 0.8
mMMgSO4, 5.5 mM D-glucose, and 50 mMHEPES, pH 7.4) and
resuspended to a final density of 1 l09 parasites/ml in loading
buffer (buffer A plus 1.5% sucrose and 5 M Fura-2/AM). The
suspension was incubated for 26 min at 26 °C with mild agita-
tion. Subsequently, the parasites were washed twice with buffer
A to remove extracellular dye, resuspended to a final density of
1  109 parasites/ml in buffer A, and kept in ice. Parasites are
viable for a few hours under these conditions. For fluorescence
measurements, 2  107 parasites/ml were placed in a cuvette
with 2.5 ml of Ringer’s solution. Fluorescence measurements
were done in a thermostatically controlledHitachi F-7000 spec-
trofluorometer using the Fura-2 conditions for excitation (340
and 380 nm) and emission (510 nm). The Fura-2 fluorescence
response to Ca2 was calibrated from the ratio of 340/380-nm
fluorescence values after subtraction of the background fluo-
rescence of the cells at 340 and 380 nm, as described previously
(43). The Ca2 release rate is the change in Ca2 concentration
during the initial 20 s after the addition of compound.
Chemical Susceptibility of P. falciparum Egress and Erythro-
cyte Invasion—Blood stage P. falciparum parasites of strain
3D7 were obtained from the Walter and Eliza Hall Institute
(Melbourne, Australia) and cultured as described previously
(44). Parasites were maintained in O human erythrocytes
(Research Blood Components, Boston, MA), at 2% hematocrit,
in RPMI 1640 supplemented with HEPES (25 mM), hypoxan-
thine (50 mg/liter), sodium bicarbonate (2.42 mM), and Albu-
max (4.31 mg/ml). Cultures were incubated at 37 °C in
microaerophilic atmospheric conditions (1% O2, 5% CO2, 94%
N2) within modular incubator chambers.
To test the specific effects of Enh1 on egress of parasites from
schizonts as well as erythrocyte invasion by liberated merozo-
ites, mature schizont stage parasites were purified from 4ml of
blood stage culture (10–20% hematocrit) by centrifugation
(930 g, 15 min, low acceleration and deceleration) on 4 ml of
a 60% Percoll cushion (45). Schizonts were retrieved from the
medium supernatant-Percoll interface. After at least three
washes in excess volumes of RPMI culture medium, schizonts
were diluted with uninfected erythrocytes for a parasitemia of
3–5% and further supplemented with 2 M Cpd2 to allow sch-
izont maturation up to the point of egress (22). After 1–4 h at
standard culture conditions, cultureswerewashed at least three
times in excess RPMI culture medium to remove Cpd2 and
added to 1 volume of Enh1 in RPMI or RPMI only (no drug) for
a sample volume of 100 l at 1% hematocrit. We similarly pre-
pared samples of parasites supplemented with heparin (100
units/ml), a specific inhibitor of erythrocyte invasion (46), to
assess the background signal for ring stage parasitemia (see
below). We fixed samples (4% paraformaldehyde and 0.0075%
glutaraldehyde in PBS (47)) at the outset of the experiment
(untreated only) and after 1–2 h of incubation in standard cul-
ture conditions (all samples). After extensive washing in PBS
and staining with SYBR Green I (1:1000 dilution in PBS; Invit-
rogen), schizont and ring stage parasitemia were measured by
flow cytometry in the FITC channel as described previously
(48, 49).
T. gondii Invasion Assays—Invasion assays were performed
as described previously (20). Briefly, freshly lysed tachyzoites
were preincubated for 10 min in varying concentrations of
Enh1, keeping the total concentration of DMSO (vehicle) con-
stant in all samples. HFF monolayers, seeded 48 h earlier, were
infected at a multiplicity of infection of10, and invasion was
allowed to proceed for 10 min at 37 °C. Following fixation,
intracellular parasites were enumerated by immunofluores-
cence and normalized to the number of host cells in a given
field.
Results
Zaprinast Increases Cytosolic Ca2 in a PKG-dependent
Manner—Previous work has shown that zaprinast triggers
T. gondii and P. falciparum egress in a PKG-dependentmanner
(20, 22). Because Ca2 is a necessary second messenger during
egress (8), we hypothesized that zaprinast might stimulate
egress by increasing cytosolic Ca2 in the parasite. To test this,
we generated a strain that expressed the genetically encoded
Ca2 indicator GCaMP5 (32) in the wild-type T. gondii recom-
binant human background. These parasites were transfected
with a plasmid encoding a constitutively secreted fluorescent
fusion protein, p30-DsRed, which accumulates in the parasito-
phorous vacuole before egress (50). This second sensor enabled
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us to visualize permeabilization of the parasitophorous vacuole,
which has been demonstrated to occur via the Ca2-regulated
secretion of a perforin-like protein (50). Human fibroblasts
infected with recombinant human GCaMP5 were treated with
zaprinast and monitored by live video microscopy. Zaprinast
elicited a rapid increase in fluorescence compared with the
vehicle alone, whichwas followed by a second, less intense peak
of fluorescence (Fig. 1,A and B). This led to permeabilization of
the vacuole membrane, as indicated by diffusion of DsRed, and
subsequent egress of the parasites from the host cell (supple-
mental Video S1).
To determine whether the zaprinast-induced increase in
Ca2 represented release of intracellular stores or Ca2 entry,
we loaded wild-type parasites with the ratiometric Ca2 indi-
cator Fura-2/AMand stimulated themwith zaprinast in buffers
containing either a basal Ca2 concentration (100 nM free
Ca2) or one resembling the extracellular environment (1.8
mM). We found that cytosolic Ca2 increased in response to
zaprinast under both conditions (Fig. 1C), although the
response was magnified in the presence of extracellular Ca2.
This indicates that zaprinast-mediated Ca2 mobilization
occurs through release of intracellular stores, which may
enhance Ca2 entry, as has been reported for other agonists
capable of releasing intracellular stores (9).
Compound 1 (Cpd1), a specific inhibitor of apicomplexan
PKG (25), blocks zaprinast-induced egress (20). To determine
FIGURE 1. Zaprinast raises cytosolic Ca2 through the activation of PKG. A, video microscopy of intracellular parasites expressing both GCaMP5 and
constitutively secretedDsRed, following the addition of zaprinast at 0 s. B, GCaMP5 fluorescence in the region of the parasitophorous vacuole (green) or DsRed
fluorescence in adjacent areas of the infected host cell (red) following the addition of zaprinast. Results shown are mean  S.E. for four experiments.
Kymographs for GCaMP5 fluorescence in all four experiments are shown to indicate times of peak fluorescence (white asterisks) relative to the initiation of
egress from the region (white vertical lines). C, intracellular Ca2 concentrations, monitored over time, for wild-type parasites loaded with Fura-2/AM, sus-
pended in buffer containing extracellular (1.8 mM) or basal (100 nM) free Ca2, and stimulated with 100 M zaprinast at 400 s. D, similar measurements were
performed for PKG-M and PKG-T parasites loadedwith Fura-2/AM and suspended in basal Ca2. Cpd1 or vehicle was added at 100 s, and zaprinast was added
at 400 s, as indicated. E–G, intracellular calcium concentrations from parasites loaded with Fura-2/AM and then treated with zaprinast, ionomycin, GPN, or
thapsigargin at 100 s (1) and 400 s (2), as indicated. Traces are representative of three independent experiments. Bar graphs report the change in cytosolic
calcium over 20 s following the addition of each drug. Results shown aremean S.E. (error bars). Z, zaprinast; I, ionomycin;G, GPN; T, thapsigargin; *, p	 0.05;
one-tailed t test.
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whether zaprinast’s effect on parasite Ca2 depends on PKG,
we measured the response to zaprinast after Cpd1 treatment.
Sensitivity of apicomplexan PKG to Cpd1 relies on the identity
of a residue at the base of theATP-binding pocket known as the
gatekeeper (25). We therefore used strains engineered to
express PKG with either the wild-type threonine or a bulky
methionine gatekeeper residue that renders PKG refractory to
Cpd1 inhibition (31). These strains were loaded with Fura-2/
AM, treated with Cpd1 or vehicle, and then stimulated with
zaprinast. Parasites treated with vehicle responded to the addi-
tion of zaprinast with a sharp Ca2 spike. The addition of Cpd1
did not change the response of the insensitive PKG-M strain.
However, the Ca2 spike was severely diminished by Cpd1 in
the sensitive PKG-T strain, indicating the need for PKG in this
process (Fig. 1D). We also observed a slight decrease in the
cytosolic Ca2 level of the PKG-T strain after Cpd1 treatment,
perhaps indicating that PKG regulates the basal Ca2 level in
addition to enhancing it before egress.
Zaprinast Mobilizes a Neutral, SERCA-independent Ca2
Store—To further characterize the source of zaprinast-mobi-
lized Ca2, we assessed the involvement of various Ca2 stor-
age organelles. We loaded parasites with Fura-2/AM and sus-
pended them in a buffer containing basal Ca2 and then added
the Ca2 ionophore ionomycin. Binding of ionomycin to Ca2
is pH-dependent and falls to negligible levels below pH 7 (51).
Ionomycin has therefore been used to specificallymobilize neu-
tral Ca2 stores in both mammalian cells (52) and T. gondii
(17). We observed a peak in cytosolic Ca2 levels following
ionomycin treatment, indicating that Ca2 had beenmobilized
from neutral stores. Subsequent treatment with zaprinast did
not produce an additional Ca2 peak, indicating that the zapri-
nast-mobilized store had already been depleted by ionomycin.
In contrast, treating parasites with zaprinast followed by iono-
mycin produced a Ca2 spike in response to each compound.
These results were corroborated by analyzing the rate of Ca2
release during the 20 s that followed the addition of each com-
pound (Fig. 1E). Taken together, these results indicate that the
zaprinast-mobilized store comprises a subset of the ionomycin-
mobilized stores and as such is predicted to be neutral.
To further rule out acidic Ca2 stores, we treated parasites
with GPN before or after the addition of zaprinast. GPN is spe-
cifically hydrolyzed in lysosomal compartments, leading to
their leakage, as has been shown for the plantlike vacuole in
T. gondii (18). As predicted by mobilization with ionomycin,
the zaprinast-mobilized store was independent from this acidic
compartment (Fig. 1F).
The ER is the major neutral Ca2 store in many organisms
(53). Thapsigargin is an inhibitor of the Ca2 reuptake pump
SERCA, which partially localizes to the ER in extracellular
T. gondii tachyzoites (54). We treated parasites with thapsi-
gargin before or after the addition of zaprinast and found that
zaprinastmobilized Ca2with the same efficiency regardless of
the treatment order. The independence of the zaprinast- and
thapsigargin-mobilized stores was evident in the rate of Ca2
release following each treatment (Fig. 1F). These results indi-
cate either that zaprinast mobilizes a neutral store that is sepa-
rate from the ER or that the ER is segmented into SERCA-de-
pendent and SERCA-independent Ca2 stores, as has been
hypothesized (4).
Identifying Small Molecules That Modulate Parasite Ca2—
Despite its central importance during infection, few com-
pounds have been demonstrated to specifically interfere with
the Ca2 signaling pathways of apicomplexan parasites. Com-
pounds that modulate Ca2 signaling can have clinical value as
well as being useful in research.We predicted that the zaprinast
response measured in GCaMP5-expressing parasites could
form the basis for a phenotypic screen. Such a screen would
benefit from the known importance of Ca2 signaling in para-
site biology along with the reported success rate of cell-based
phenotypic assays. We designed a screen wherein extracellular
GCaMP5-expressing parasites were pretreated with com-
pounds for 10 min before stimulation with zaprinast, and par-
asite fluorescence was measured 4 min later. We expected that
compounds that interfered with the zaprinast response would
reduce fluorescence. We calculated a Z-factor for this screen
to determine its dynamic range and suitability to high through-
put screening. To do so, we compared zaprinast-treated para-
sites to untreated parasites or those pretreated with the PKG
inhibitor Compound 2 (Cpd2) (55). These scenarios yielded
Z-factors of 0.58 and 0.55, respectively, well above the 0.5
Z-factor considered acceptable for high throughput screening
(56). This phenotypic screen is therefore suitable for analyzing
large libraries of compounds to identify compounds interfering
with parasite Ca2 signaling (Fig. 2A).
We obtained the compound libraries published kinase inhib-
itor sets PKIS1 (57) and PKIS2 (unpublished), from Glaxo-
SmithKline and applied our phenotypic screen to the 823 ATP
mimetics represented in these collections (Fig. 2B and supple-
mental Table S1). The compounds were screened at a single 10
M dose with two biological replicates. We identified 37 puta-
tive inhibitors and 14 putative enhancers, defined as com-
pounds that resulted in fluorescence readings that were more
than twoS.D. values belowor above themeanof all compounds,
respectively. Compounds that interfered with accurate mea-
surement of GCaMP5 fluorescence, including two putative
enhancers, were identified and excluded from subsequent
experiments.
Wewonderedwhetherwe could identify classes ofmolecules
that inhibit or enhance Ca2 mobilization. To this end, we
examined analogs of the most potent enhancer and inhibitor,
which we here refer to as Enh1 (PKIS: GSK260205A) and Inh1
(PKIS: GW827099X) (Fig. 2C). Compounds with the same core
structure as Enh1 generally produced a -fold change in fluores-
cence of
1 in our screen, indicating that parasite fluorescence
was greater in the presence of such compounds thanwith zapri-
nast alone (Fig. 2D and supplemental Fig. S1). A Kolmogorov-
Smirnov test comparing the values obtained from all com-
pounds with those obtained from the Enh1 analogs revealed a
significant difference (p  0.0042) (Fig. 2D). The combination
of a phenyl group at the R1 position and a 3-aminopropyloxy
group at the R3 position, as found in Enh1, appeared to produce
a particularly effective enhancer; compounds having either
group without the other produced only a mild effect. A similar
analysis of Inh1 analogs revealed that these compounds tended
to inhibit zaprinast-induced Ca2 mobilization (Fig. 2D and
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supplemental Fig. S2). The fluorophenyl group in the R1 posi-
tion of Inh1 may be responsible for this compound’s strong
inhibitory effect (as discussed below). This 4-fluorophenyl is
also found inCpd1 andCpd2.No other R1 side group produced
a similarly strong response, although an analogue containing a
trifluoromethyl group at the R1 position elicited the second
largest response in the group. In summary, although Enh1 and
Inh1 are unique within the set of compounds tested for their
abilities to augment and repress cytosolic Ca2, their core
structures appear to be generally well suited to these purposes.
Indeed, further exploration of these scaffolds could lead to the
identification of improved modulators of parasite Ca2
signaling.
Two Inhibitors Target PKG Using Distinct Chemical Scaf-
folds—Because known PKG inhibitors could suppress zapri-
nast-induced Ca2 release (Fig. 1D), we hypothesized that the
newly identified compounds could act in a similar manner. We
tested the effects of Inh1 and Inh2 (compound GW407323A
from the screen) on the in vitro activity of recombinant T. gon-
dii PKG. Both compounds inhibited PKG activity with IC50
values of 580 nM for Inh1 and 670 nM for Inh2 (Fig. 3A), sug-
gesting that PKG inhibition is a plausible explanation for their
activity. Furthermore, neither inhibitor showed appreciable
activity against human PKG or related AGC kinases (57), dem-
onstrating selectivity for the parasite enzyme.
The two inhibitors are derivatives of distinct bicyclic heter-
ocyclic scaffolds with proven activity against protein kinases.
Inh1 is a PP with substitutions in the C2 and C3 positions (Fig.
3B). Several available kinase structures display a similar orien-
tation of the PP scaffold in theATP-binding pocket, with theC3
position engaging the hinge region and theC2position oriented
toward the gatekeeper residue. The structures of two such
inhibitors complexed with human CDK2 demonstrate the
proximity of the C2 position to the bulky phenylalanine-gate-
keeper residue (Fig. 3B, middle). Substitutions at this position
decreased the activity of these inhibitors presumably due to
steric clash with the gatekeeper (36). The 4-fluorophenyl group
in the C2 position of Inh1 is therefore expected to restrict bind-
ing of the inhibitor to kinases with relatively small gatekeepers,
like the threonine found in T. gondii PKG. This type of binding
is evident in the structure of p38MAPKwith a ligand similar to
Inh1 (SB203580, a monocyclic heterocycle rather than a bicy-
clic one) that extends the 4-fluorophenyl functional group into
the hydrophobic pocket created by a threonine gatekeeper (37)
(Fig. 3B, right). Furthermore, the related human kinase ERK2,
normally resistant to SB203580, can be rendered sensitive to
this inhibitor by mutation of its gatekeeper glutamine to either
an alanine or a threonine (58). This strongly suggests that a
small gatekeeper is required to accommodate heterocycles with
substitutions similar to those found on Inh1.
Inh2 is an oxindole derivative, with substitutions at the C3
and C5 positions (Fig. 3C). Disubstituted and trisubstituted
oxindoles are well studied protein kinase inhibitors. Several
structures are available of kinases in complex with such inhib-
itors. In every instance, the oxindole is positioned such that the
2-oxygen and the nitrogen of the bicyclic scaffold engage the
hinge residues (Fig. 3C, left). This configuration leaves the C3
and C5 positions pointing away from the binding pocket.
Although the C6 substituent is inward pointing, it does not
approach the direction of the gatekeeper. The binding config-
uration of oxindole derivatives is highly consistent across
several different kinase structures, suggesting that Inh2
(a 3,5-disubstituted oxindole) is likely to be gatekeeper-independent.
FIGURE 2. Compound screen identifies modulators of zaprinast-induced Ca2 signaling. A, GCaMP5-expressing parasites pretreated with Cpd2 or a
vehicle control were stimulated with zaprinast or a vehicle control, and fluorescence was measured to determine a Z score for a zaprinast-based screen for
Ca2modulators. B, GCaMP5-expressing parasites were pretreated with 823 compounds from the PKIS libraries. Fluorescence was measured after zaprinast
stimulation. Results are -fold change from zaprinast alone after background subtraction. Compounds that fluoresced independently are indicated (blue) along
with selectedenhancers (Enh;green) and inhibitors (Inh; red). ThemeanS.D. (error bars) of twoexperiments is shown, anddashed lines indicate twoS.D. values
above and below the mean of all compounds. C, structures of Enh1, Enh2, Inh1, and Inh2 as well as the known PKG inhibitors: Cpd1 and Cpd2. D, cumulative
frequencies of screen values for all compounds (black), Inh1 and its analogs (red), or Enh1 and its analogs (green).
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To determine whether these inhibitors could interfere with
other PKG-dependent processes, we next assessed their ability
to block zaprinast-induced egress.We directly tested the struc-
tural predictions regarding the effect of the gatekeeper on Inh1,
but not Inh2, by performing these experiments with the
PKG-M and PKG-T strains. We measured zaprinast-induced
egress by lactate dehydrogenase release from host cells infected
with either strain (Fig. 3D). As expected, PKG-T parasites did
not egress after Cpd2 treatment, whereas the refractory
PKG-M strain egressed similarly to vehicle-treated parasites.
Both Inh1 and Inh2 reliably reduced egress relative to vehicle-
treated parasites. The similar potencies of these compounds in
vivo and in vitro are consistent with inhibition of PKGbeing the
primary mechanism through which Inh1 and Inh2 block egress
(Fig. 3D). As predicted from our structural analysis, Inh1
worked in a gatekeeper-dependent manner, reducing egress
from cells infected with PKG-T parasites with an IC50 of 1.3M
but leaving PKG-M parasites unaffected. In contrast, Inh2
reduced egress from cells infected with either strain, exhibiting
an IC50 of 2.5 M for PKG-T and 3.5 M for PKG-M. These
results were satisfying because we were able to recover inhibi-
tors with distinct scaffolds and modes of inhibiting an enzyme
known to be involved in the zaprinast response. Identification
of two novel PKG inhibitors through a screen of only 823 com-
pounds demonstrates the power of our approach to identify
compounds with biological effects in pathways critical to para-
site survival.
Two Enhancers Directly Release Intracellular Ca2 Stores—
Having shown that a screen for modulators of zaprinast-in-
duced Ca2 mobilization reveals novel PKG inhibitors, we
turned our attention to Enh1 and another putative enhancer:
Enh2, or GSK2188764A (Fig. 2C). During the course of this
study, the genetically encoded Ca2 indicator GCaMP6f
became available. Because GCaMP6f has a broader dynamic
range and faster kinetics thanGCaMP5 (59), we usedGCaMP6f
throughoutmuch of this study.We tested whether the enhanc-
ers could increase parasite Ca2 independently of zaprinast.
Indeed both enhancers could mobilize Ca2 on their own,
although they did so with significantly slower kinetics than
zaprinast (Fig. 4A).
To determine the source of the Ca2 mobilized by the
enhancers, we suspended parasites in buffers containing extra-
FIGURE 3. PKG inhibitors display distinct modes of inhibition. A, activity of recombinant PKG in the presence of increasing concentrations of Inh1, Inh2, or
the PKG inhibitor Cpd2. B, binding of PP derivatives like Inh1 to protein kinases orients the C2 position toward the gatekeeper residue (orange). Left, the PP
scaffold’s orientation for a disubstituted PP in complex with CDK2. Middle, the structure of Inh1 is highlighted to indicate the PP scaffold (red) and the C2
fluorophenyl group (green). Two other similar compounds fromother kinase structures are superimposed over the CDK2 structure in complexwith its inhibitor,
all showing a similar positioning of the PP scaffold. Right, human p38 MAPK with a trisubstituted monocyclic heterocycle oriented similarly as the PP scaffold
and extending a fluorophenyl group in the direction of the gatekeeper. C, oxindole derivatives bind to protein kinases in amanner that orients their C2 and C5
positions away from the gatekeeper. Left, oxindole scaffold of a derivative in complex with NEK2. Right, the oxindole scaffold of Inh2. Two other similar
compounds from other kinase structures have been superimposed on the structure of NEK2with its inhibitor.D, zaprinast-induced egress of parasites carrying
Cpd2-sensitive (PKG-T) or resistant (PKG-M) alleles of PKG, following pretreatment with Inh1, Inh2, or Cpd2. Results shown are mean S.E. (error bars) for n
3 independent experiments.
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cellular (1 mM) or basal (100 nM) levels of free Ca2, treated
these parasites with 10 M Enh1 or Enh2, and monitored
GCaMP6f fluorescence (Fig. 4A). Enh1 increased fluorescence
under both conditions, indicating that it mobilizes intracellular
stores. Surprisingly, we observed only weak mobilization of
Ca2 in response to Enh2 under both conditions. Because the
original screen was performed in buffer containing 1% FBS, we
tested the effect of this component. The addition of 1% FBS
increased Enh2-mediated Ca2 mobilization. We interpreted
this to mean that Enh2 requires a cofactor found in FBS.
Because the activity of Enh2 is relatively weak and depends on
specific conditions, we focused subsequent experiments on
Enh1.
We wondered whether, like zaprinast, Enh1 functions
through PKG to increase parasite Ca2. Significant overlap in
the emission spectra of Enh1 and Fura-2 prevented us from
using this ratiometric indicator. However, we were able to use
GCaMP6f to make semiquantitative measurements. We
recorded fluorescence from GCaMP6f-expressing parasites
treated with Cpd1 or vehicle control, followed by stimulation
with Enh1 or zaprinast. To record the peak fluorescence
induced by zaprinast, we had to incubate parasites on ice before
stimulation so as to slow down the response. In contrast to the
zaprinast response, Cpd1-treated parasites responded to Enh1
in the samemanner as vehicle-treated parasites, indicating that
Enh1 does not act through PKG. Although Cpd1 accelerated
the return to basal Ca2 levels following zaprinast treatment, it
only partially decreased the initial Ca2 spike induced by zapri-
nast (Fig. 4B). This is reminiscent of results obtained fromFura-
2-loaded parasites, where the increase in Ca2 following zapri-
nast could never be fully suppressed by PKG inhibition
(Fig. 1D).
We wondered whether zaprinast or Enh1 could induce Ca2
fluxes in mammalian cells. We transfected HeLa cells with the
plasmid CMV-R-GECO (42), which encodes a variation of the
GCaMP Ca2 indicators under the mammalian CMV pro-
moter. We treated these transfected cells with zaprinast, Enh1,
or, as a positive control, the Ca2 ionophore A23187. Video
microscopy revealed that R-GECO-expressing HeLa cells
increased fluorescence in response to A23187 but that neither
zaprinast nor Enh1 produced a significant change (Fig. 4C).
Given that zaprinast is known to inhibit phosphodiesterases in
mammalian cells (60), we considered that these drugs could be
having a subtle effect that was below our limit of detection.We
therefore repeated the assay with greater spatial and temporal
resolution. We observed a slight increase in R-GECO fluores-
cence in response to zaprinast during the first 10 s of treatment.
However, Enh1 had no effect on host cell Ca2 (Fig. 4D), indi-
cating that the effects of Enh1 are specific to Ca2 signaling in
the parasite.
Enh1 Inhibits T. gondii Survival—Zaprinast and related
phosphodiesterase inhibitors were recently shown to block
T. gondii proliferation in human fibroblasts (61). Altering Ca2
levels using ionophores has also been shown to affect parasite
viability (62).We therefore hypothesized that Enh1 would sim-
ilarly inhibit survival of T. gondii. We tested the effect of these
compounds using plaque assays as an indication of parasite sur-
vival following treatment with Enh1 or zaprinast. Plaque for-
mation was inhibited by zaprinast and Enh1 at 100 and 0.5 M,
respectively, whereas 10-fold lower concentrations allowed
normal plaque formation similar to vehicle alone (Fig. 5A).
These results for zaprinast agree with previously published
work (61). In order to determine the inhibitory concentrations
of these compounds more precisely, we performed lytic assays
in which host cells were exposed to parasites pretreated with
varying concentrations of zaprinast or Enh1, and the degree of
host cell lysis was assessed by crystal violet staining of the
monolayer, 3 days later. Enh1 showed a steep dose response,
with 350 nM completely inhibiting parasite-induced cell death,
and an EC50 of 180 nM. In contrast, 500 M zaprinast was
required to cause complete inhibition of parasite-induced cell
death, and the IC50 of zaprinast was 200 M (Fig. 5B).
Wenoticed the discrepancy between the amount of zaprinast
required to kill T. gondii in plaque assays (100 M) and the
FIGURE 4. Enh1 and Enh2 mobilize intracellular Ca2 stores. A, GCaMP6-
expressing parasites suspended in buffer supplementedwith either extracel-
lular (1 mM) or basal (100 nM) Ca2 concentrations, with or without 1% FBS,
and treated with 10 M Enh1 or Enh2 at time 0. B, GCaMP6-expressing para-
sites treated with 1 M Cpd1 or vehicle at 100 s and then with 10 M Enh1 or
100 M zaprinast at 400 or 750 s, respectively. A gap indicates incubation on
ice before the addition of zaprinast, in order to capture the peak of the
response. Measurements represent fluorescence after the subtraction of
background obtained from samples treated with Cpd1 or vehicle, as indi-
cated. Results shown are mean  S.E. (error bars) for n  3 independent
experiments. C andD, intensity of R-GECO-expressing HeLa cells treatedwith
Enh1, zaprinast, or A23187over 10min (C) or acquired at a faster rate for 1min
(D).
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amount needed in lytic assays (500 M). Because a rise in cyto-
solic Ca2 stimulates parasite motility (2), we wondered if the
movement of T. gondii in response to concentrations between
100 and 500 M might mechanically wound and kill host cells,
which would be indistinguishable from parasite survival in the
lytic assay. We tested this hypothesis by incubating host cell
monolayers with parasites pretreated with various concentra-
tions of zaprinast and then measuring lactate dehydrogenase
release from host cells. We found that treatment with 64–510
M zaprinast resulted in host cell lysis, with a maximal effect at
130 M. Host cell lysis was not observed with zaprinast in the
absence of T. gondii (Fig. 5C). Due to the lower multiplicity of
infection used in plaque assays compared with lytic assays, host
cells in plaque assays would be unlikely to experience observ-
able cell wounding. We therefore expect the plaque assays to
provide a more accurate measure of zaprinast’s antiparasitic
activity.
Enh1 Induces Asynchronous Ca2 Fluxes—We thought it
likely that the plaquing defect caused by Enh1was related to the
Ca2 disregulation induced by this compound. We therefore
characterized the Ca2 response to Enh1 in more detail. We
recorded videos of intracellular GCaMP6f-expressing parasites
treatedwith Enh1 and compared the resultwith zaprinast treat-
ment, which we have shown induces egress. We observed
GCaMP6f activity in both cases, indicating that Enh1 can act on
intracellular parasites. However, the profiles of zaprinast and
Enh1-mediated Ca2 mobilization were remarkably different.
Whereas zaprinast induced a fast, strong Ca2 peak (Fig. 6A
and supplemental Video S2), Enh1 elicited a slow, asynchro-
nous effect in which some parasites appeared to experience
multiple Ca2 fluxes of similar magnitudes over the course of
several minutes (Fig. 6A and supplemental Video S3). The
response to these compounds was similar in extracellular par-
asites (data not shown).
We generated kymographs illustrating the responses of indi-
vidual GCaMP6f parasites to Enh1. Wondering whether pre-
treatment with Enh1 would affect the ability of parasites to
respond to other Ca2 agonists, we treated some of these par-
asites with zaprinast as well (Fig. 6B). The sporadic flashes of
Ca2 triggered by Enh1 were recapitulated, and all vehicle-
treated parasites experienced an increase in Ca2 immediately
after the addition of zaprinast.However, Enh1-treated parasites
varied in their responses to zaprinast, exhibiting asynchronous
Ca2 fluxes and inconsistent magnitudes in their Ca2
increases. In rare cases, Ca2 concentrations in Enh1-treated
parasites even dropped upon zaprinast treatment. We quanti-
fied the changes in fluorescence of individual parasites over the
40 s following zaprinast addition and observed a more varied
and overall diminished response to zaprinast in Enh1-treated
parasites (Fig. 6C). Taken together, these results suggest that
Enh1 may partially deplete the Ca2 stores mobilized by
zaprinast.
Enh1 Blocks Ca2-related Phenotypes in T. gondii and
P. falciparum—While examining Enh1-treated parasites, we
noticed that this compound did not induce egress and in fact
suppressed egress in response to zaprinast (Fig. 6C). To confirm
these effects, we treated intracellular GFP-expressing parasites
with Enh1 and quantified the number of intact vacuoles at var-
ious times after treatment, using fluorescence to monitor the
infection using automated image analysis. This assay is capable
of directly measuring egress for hundreds of vacuoles per sam-
ple. Surprisingly, despite its effects on extracellular parasites,
Enh1 failed to stimulate egress beyond the spontaneous egress
observed in the vehicle control. In contrast, zaprinast treatment
resulted in90% of vacuoles egressing within 30 min (Fig. 7A),
as described previously (20). We then examined the effect of a
10-min Enh1 pretreatment and found that it robustly blocked
zaprinast-induced egress. Analysis of the dose-dependent inhi-
bition of egress by Enh1 revealed an EC50 of 290 nM, within the
range of concentrations that inhibit plaque formation (Fig. 7B).
These results suggest that the antiparasitic activity of Enh1 is
mediated by its inhibition of parasite egress.
We wondered whether we could generalize the Enh1-associ-
ated egress defect beyond zaprinast-induced egress. We there-
fore tested the ability of Enh1 to block egress induced by the
Ca2 ionophore A23187. Enh1 also produced a significant
block on A23187-induced egress (Fig. 7C), demonstrating that
its effects on parasite Ca2 signaling extend to a variety of
agonists.
We tested whether Enh1 also affects other apicomplexan
parasites that use Ca2-based signal transduction. Asexual,
blood stage Plasmodium parasites undergo Ca2-dependent
egress from infected erythrocytes, followed byCa2-dependent
invasion into new erythrocytes (6, 63). To assess the effect of
Enh1 on these processes at the relevant developmental stage,
we allowed purified schizonts to complete their intracellular
maturation while blocked with Cpd2 from rupturing and
egressing (22).We administered Enh1 to parasites immediately
FIGURE 5. Enhancers of Ca2mobilization show antiparasitic activity. A,
plaque formation in the presence of the indicated concentrations of Enh1 or
zaprinast. The drug concentrations indicated did not affect host cell survival.
B, dose-dependent effect of Enh1 and zaprinast on parasite viability, assayed
bymonolayer disruption, 3 days postinfection, at the indicated drug concen-
trations. Results shown are mean  S.E. (error bars) for n  3 independent
experiments. C, host cell lysis following 1 h of infection in the presence of
varying zaprinast concentrations.
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following washout of Cpd2. After allowing 1–2 h of incubation
with the compound, wemeasured egress and reinvasion using a
flow cytometry-based assay that distinguishes schizonts from
recently invaded ring stage parasites (49). Whereas Enh1 does
not reduce parasite egress at concentrations up to at least 10M
(Fig. 7D), the compound completely blocks invasion within the
tested range (IC50  3.2 M) (Fig. 7E). Wondering whether
Enh1 could also inhibit invasion in T. gondii, we incubated
tachyzoites with varying doses of Enh1 for 20 min and tested
their ability to infect host cells. As in P. falciparum, Enh1
strongly inhibitedT. gondii invasion (Fig. 7F). Furthermore, the
IC50 of Enh1 in the invasion assay was 180M, similar to that in
the egress assay, arguing for a common mechanism for the
effect of Enh1 on both Ca2-related phenotypes. In summary,
Enh1modulates Ca2-dependent processes in diverse apicom-
plexan parasites.
Discussion
Ca2 signaling plays a central role in apicomplexan biology,
yet few of the components that regulate Ca2 uptake and
release have been identified. In this study, we extend our under-
standing of these processes by demonstrating that PKG activity
is needed for the robust Ca2 response elicited by phosphodi-
esterase inhibitors. Furthermore, we determine the source of
Ca2 to be distinct from other previously described stores. We
use this phenomenon as the basis of a phenotypic screen that
allowed us to identify several novel inhibitors and enhancers of
Ca2 signaling. Two of the inhibitors could be shown to inter-
fere with Ca2 signaling by specifically targeting parasite PKG.
In contrast, the enhancers could be shown to increase Ca2
independently from zaprinast and in fact prevented parasite
egress by apparently depleting intracellular Ca2 stores. This
compound displayed antiparasitic properties against both
T. gondii and P. falciparum, establishing a new mechanism for
interfering with apicomplexan parasitism.
The signaling events that trigger parasite egress remain
poorly defined. Ca2 ionophores have long been known to
stimulate egress in T. gondii (64). However, more recently,
phosphodiesterase inhibitors were shown to have similar
effects (20, 61). Our experiments revealed a strong and rapid
FIGURE 6. Enh1 elicits asynchronous cytosolic Ca2 fluxes and blocks zaprinast-induced egress. A, video microscopy of GCaMP6f-expressing parasites
treated with Enh1 or zaprinast. Time after the addition of the compound is indicated. Different times were used to capture the fast and slow responses of
zaprinast and Enh1, respectively. B, kymographs illustrate average fluorescence intensities of individual parasites, per row, during the course of the treatment
indicated. Black indicates that parasites egressed from vacuoles. C, change in fluorescence of the parasites illustrated in B over the 40 s following the addition
of zaprinast. Measurements from each biological replicate are colored separately. Mean change for each group is indicated with a horizontal line. ****, p 	
0.0001, two-tailed t test.
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release of Ca2 in response to zaprinast treatment through the
use of both the establishedCa2 indicator Fura-2 and the newly
adapted genetically encoded sensors GCaMP5 and GCaMP6f
(29).We provide conclusive evidence linking PKG to the zapri-
nast-induced increase in cytosolic Ca2, using a chemical-ge-
netic approach to demonstrate specific inhibition of PKG by
Cpd1 and Cpd2. Sensitivity to both inhibitors depends on the
relatively small gatekeeper of apicomplexan PKGs, which we
mutated to a methionine that preserves kinase activity but ren-
ders PKG refractory to inhibition (31). The changes in the
zaprinast response caused byCpd1 can therefore be fully attrib-
uted to PKG because no such changes were observed upon
treatment of the resistant strain (PKG-M). However, compar-
ing the response to zaprinast in parasites pretreated with Cpd1
with those pretreated with vehicle shows that the initial sharp
Ca2 peak induced by zaprinast is incompletely suppressed by
Cpd1, in contrast to its complete inhibition of zaprinast-in-
duced egress (20). Suppression of this peak appeared greater
when assayed using Fura-2 (Fig. 1D) than when using GCaMP6
(Fig. 4B). This may result from the semiquantitative nature of
GCaMP6 and the potentially non-linear relationship between
fluorescence andCa2 concentration. Additionally, differences
in the subcellular distribution of the two indicators may influ-
ence their responses to different sources of Ca2. Ratiometric
measurements with Fura-2 also revealed that inhibition of PKG
by Cpd1 decreased basal Ca2 concentrations in extracellular
parasites, suggesting that PKGmight also be necessary tomain-
tain resting levels of Ca2 in extracellular parasites. These
changes in basal Ca2 concentrationsmight not be evidentwith
GCaMP6f due to its higherKd (375 nM) (59) comparedwith that
of Fura-2 (135 nM) (43).
We characterized the zaprinast-mobilized store as neutral
because it can be depleted by ionomycin. However, we found
that this store is independent of the thapsigargin-mobilizable
store. This is surprising, given that the ER is the only neutral
Ca2 store that has been characterized inT. gondii. SERCA, the
target of thapsigargin, localizes to the ER in intracellular para-
sites but redistributes so as to only partially colocalize with the
ER in extracellular parasites (54). Because our experiments
were done in extracellular parasites, it is possible that zaprinast
mobilizes Ca2 from a section of the ER lacking SERCA under
these conditions, as previously suggested for the ethanol-mobi-
lized Ca2 stores (65). In P. falciparum, zaprinast has been
shown to work through P. falciparum PKG to trigger changes
in the levels of various precursors of the second messenger IP3.
Presumably, this increases IP3, which then interacts with the
IP3 receptor to stimulate release of Ca2 from intracellular
stores (19). An IP3 receptor has not been identified in apicom-
plexans, but treating parasites with ethanol raises levels of IP3
and stimulates Ca2 release, providing evidence for the pres-
ence of such a channel (66). Our results therefore indicate that
zaprinast functions, at least in part, through T. gondii PKG and
probably mobilizes a neutral, SERCA-independent, IP3 recep-
tor-gated store.
Genetically encoded calcium indicators provide excellent
reproducibility and circumventmany problems associatedwith
loading and compartmentalization of chemical probes.Herewe
demonstrate that such indicators can be used to identify com-
pounds that alter apicomplexan Ca2 signaling and its depen-
dent processes, such as egress and invasion. The simplicity and
robustness of this cell-based phenotypic screen, with a Z-fac-
tor
0.5, makes it compatible with high throughput screening
efforts. As proof of concept, we screened a library of 823 ATP
mimetics from GlaxoSmithKline for compounds that could
alter the zaprinast-induced increase in cytosolic Ca2. Identi-
fication of two PKG inhibitors, with distinct chemical scaffolds
and mechanisms of inhibition, validated our screen and dem-
onstrates the power of the approach. Unexpectedly, our screen
FIGURE 7. Enh1 blocks egress Ca2-related phenotypes in T. gondii and
P. falciparum.A, egress of intracellular parasites treatedwith zaprinast, Enh1,
or a vehicle control. The number of intact vacuoles was monitored by live
microscopy over 30 min. Representative images before and after treatment
are shown. B, dose-dependent inhibition of zaprinast-induced egress follow-
ingpretreatmentwithEnh1or vehicle.C, Enh1 inhibitionof egress inducedby
either zaprinast or A23187. Results shown aremean S.E. (error bars) for n
3 independent experiments. ***, p	 0.001; **, p	 0.01. D–E, schizonts were
released from Cpd2 arrest immediately preceding the addition of Enh1. D,
after 1–2 h, the remaining schizonts (mean  S.D. for three technical repli-
cates) were counted and normalized to their initial abundance (3.6 and 5.4%
in each experiment, respectively). E, Enh1 blocks invasion of erythrocytes by
P. falciparum, measured 1–2 h following release from Cpd2, as assessed from
the ring stage parasitemia. Mean invasion S.E. is expressed as a percentage
of invasion without drug (9.5 and 8.1% in each experiment, respectively).
Background was assessed using heparin as a specific blocker of invasion and
was comparable with the signal observed with saturating concentrations of
Enh1. F, dose-dependent inhibition of T. gondii invasion following 10-min
pretreatment of parasites before invasion. Results shown aremean S.E. for
n 3 independent experiments.
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also revealed two compounds that, when used in combination
with zaprinast, augmented Ca2 levels. One such compound,
Enh1, elicited repeated cycles of Ca2 increase and decrease
with overall cytosolic Ca2 building at a population level. These
repeated cycles are reminiscent of what others have seen when
Fluo-4/AM-loaded parasites were treated with thapsigargin
(54), perhaps indicating that Enh1 also inhibits Ca2 uptake
pathways.
In contrast to zaprinast and Ca2 ionophores, Enh1 failed to
stimulate egress despite raising cytosolic Ca2 levels. In fact,
Enh1 blocked the ability of these agonists to stimulate parasite
egress. Furthermore, treatment with Enh1 blocked tachyzoite
invasion and plaque formation at concentrations similar to
those required to block egress. These results suggest that Enh1
depletes essential intracellular Ca2 stores, which have been
previously suggested to mediate invasion and egress. Consist-
ent with this view, we observed diminished changes in GCaMP
fluorescence in response to zaprinast, following Enh1 treat-
ment (Fig. 6C). However, without a complete understanding of
Enh1 function, we cannot rule out the possibility that inhibition
of egress may be independent of its ability to modulate Ca2
because (i) some parasites in which Enh1 did not elicit Ca2
fluctuations still failed to egress in response to zaprinast, and
(ii) A23187, which should equilibrate Ca2 across membranes,
failed to overcome Enh1 inhibition. Compounds similar to
Enh1 have been shown to inhibitmammalian kinases belonging
to the AGC family (67). Having already established that T. gon-
dii PKG, a member of the AGC kinase family, mediates Ca2
release, it is an intriguing possibility that a related kinase might
oppose its activity.
Enh1 robustly inhibited the ability of P. falciparum to invade
erythrocytes, although it did not affect egress. Despite themany
parallels between egress of P. falciparum and T. gondii, sub-
stantial differences have also been uncovered. Plasmodium
egress is a fast, highly synchronized process, dependent on a
cascade of proteolytic activity (68). Genetic evidence supports
this distinctionwithmutants in the calcium-responsive protein
DOC2.1 blocking both egress and invasion inT. gondii but only
invasion in P. falciparum (69), mirroring the effects of Enh1.
The intracellular Ca2 stores of Plasmodium have not been
investigated as thoroughly as those of T. gondii, but there is
some evidence that it is not solely dependent on its intracellular
Ca2 stores and in fact utilizes Ca2 found within the parasito-
phorous vacuole (70). In light of this, the differential responses
of P. falciparum and T. gondii to Enh1 are perhaps not surpris-
ing. That Enh1 blocks invasion of P. falciparum demonstrates
this compound’s ability to perturb Ca2-dependent processes
across multiple members of the Apicomplexa.
Resistance to front line antimalarials is increasing (71, 72),
and new treatment options are needed. Rational design strate-
gies can identify drugs withminimal off-target effects but focus
on a limited repertoire of signaling pathways. The Toxoplasma
Ca2 signaling network shows evidence of conservation within
apicomplexans while being dissimilar to human signaling path-
ways. By screening for modulation of this pathway, we have
prioritized compounds that are likely to interfere selectively
with infection without focusing on a single parasite protein.
This screen can be performed with commonly available equip-
ment and should be easily scalable to larger collections of com-
pounds. Our success in identifying new modulators of Ca2
signaling with effects that extend to multiple apicomplexans
highlights the power of such an approach. In particular, Enh1
inhibits parasite viability with an EC50 in the nanomolar range
and provides a good lead for the development of antiparasitic
compounds. Further characterization of these compoundsmay
identify novel components of apicomplexan Ca2 signaling
pathways and improve our ability to target these pathways
specifically.
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